Who
Robert E. Gagnon
Director
Company insider
Files Form 4 as: Director, Bone Biologics; Chief Financial Officer, Opus Genetics; Chief Financial Officer, Harvard Bioscience; Chief Financial Officer, Verastem; EVP CFO and Treasurer, Clean Harbors; Vice President, Finance, Biogen.
In numbers
- Trades disclosed
- 190
- Buys
- 6
- Sells
- 60
- Bought
- $94K
- Sold
- $4.5M
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 1 Dec 2010
- Last trade
- 28 Sep 2026
- Last filed
- 30 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Sep 2026filed 30 Sep 2026 | BBLG Bone Biologicsoption or derivative · Medical Devices | SEC FORM 4 Code A | —113,896 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | BBLG Bone Biologicsoption or derivative · Medical Devices | SEC FORM 4 Code A | —113,896 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $127K28,000 at $4.54 | filing |
| 3 Sep 2026filed 8 Sep 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $127K28,000 at $4.54 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $23K7,783 at $2.95 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $23K7,783 at $2.95 | filing |
| 9 Jun 2026filed 11 Jun 2026 | HBIO Harvard BioscienceLife-science tools | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | HBIO Harvard BioscienceLife-science tools | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $41K7,842 at $5.18 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $41K7,842 at $5.18 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Sold | $2,587283 at $9.14 | filing |
| 16 Sep 2025filed 18 Sep 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Sold | $2,807281 at $9.99 | filing |
| 10 Sep 2025filed 11 Sep 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Sep 2025filed 11 Sep 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | HBIO Harvard BioscienceLife-science tools | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 16 Jun 2025filed 20 Jun 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Sold | $1,605284 at $5.65 | filing |
| 4 Jun 2025filed 6 Jun 2025 | BBLG Bone Biologicsoption or derivative · Medical Devices | SEC FORM 4 Code A | —62,894 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Verastem (NASDAQ:VSTM) Stock Price Target Raised at MizuhoVSTM · tickerreport.com · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?VSTM · tickerreport.com · 14 Oct 2026Verastem (NASDAQ:VSTM) Stock Falls 7% – Here's What HappenedVSTM · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Robert E. Gagnon; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.